Revolutionizing drug discovery for neurological diseases

Right Tissue + Right Target = Right Drug

EverTree’s proprietary platform technology enables us to create and test any type of neurological tissue derived from human pluripotent stem cells with unprecedented precision. Combined with our proprietary Machine Learning capabilities, this unlocks the ability to assess drug efficacy prior to animal testing, making drug development faster, less expensive, more predictable, and more accurate.

Restoring Glial Health Through Myelination and Neuroprotection

We seek to restore neurological function by repairing glial cells, the crucial support cells in our nervous system.

EverTree’s Lead Program: Myelination Disorder (CMT1A)

Our lead program is a small molecule for Charcot-Marie-Tooth Disease Type 1A (CMT1A). With ~70,000 US patients, CMT1A is twice as prevalent as ALS, yet has no FDA-approved treatments. CMT1A is the perfect proof of concept to demonstrate how EverTree’s platform technology can accomplish what was previously impossible.

EverTree’s Additional Programs

Our pipeline is poised for expansion. Additional programs include ALS, Multiple Sclerosis and Pain.